A replicative self-renewal model for long-lived plasma cells: Questioning irreversible cell cycle exit

Frontiers in Immunology

Volumn 4, Issue DEC, 2013, Pages

  Tooze, Reuben M ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Cell cycle; Gene expression; Lifespan; Monoclonal gammopathy; Myeloma; Plasma cell; Quiescence; Self renewal

Indexed keywords

EID: 84892164900     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00460     Document Type: Article

References (136)

1. Chen-Kiang S. Cell-cycle control of plasma cell differentiation and tumorigenesis. Immunol Rev (2003) 194:39-47. doi:10.1034/j.1600-065X.2003.00065.x
2. Amanna IJ, Slifka MK. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev (2010) 236:125-38. doi:10.1111/j.1600-065X.2010.00912.x
3. Oracki SA, Walker JA, Hibbs ML, Corcoran LM, Tarlinton DM. Plasma cell development and survival. Immunol Rev (2010) 237:140-59. doi:10.1111/j.1600-065X.2010.00940.x
4. Yoshida T, Mei H, Dorner T, Hiepe F, Radbruch A, Fillatreau S, et al. Memory B and memory plasma cells. Immunol Rev (2010) 237:117-39. doi:10.1111/j.1600-065X.2010.00938.x
5. Slocombe T, Brown S, Miles K, Gray M, Barr TA, Gray D. Plasma cell homeostasis: the effects of chronic antigen stimulation and inflammation. J Immunol (2013) 191:3128-38. doi:10.4049/jimmunol.1301163
6. Miller JJ III. An autoradiographic study of plasma cell and lymphocyte survival in rat popliteal lymph nodes. J Immunol (1964) 92:673-81.
7. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity (1998) 8:363-72. doi:10.1016/S1074-7613(00)80541-5
8. Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature (1997) 388:133-4. doi:10.1038/40540
9. Gatto D, Martin SW, Bessa J, Pellicioli E, Saudan P, Hinton HJ, et al. Regulation of memory antibody levels: the role of persisting antigen versus plasma cell life span. J Immunol (2007) 178:67-76.
10. Rozanski CH, Arens R, Carlson LM, Nair J, Boise LH, Chanan-Khan AA, et al. Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. J Exp Med (2011) 208(7):1435-46. doi:10.1084/jem.20110040
11. Ho F, Lortan JE, Maclennan IC, Khan M. Distinct short-lived and long-lived antibody-producing cell populations. Eur J Immunol (1986) 16:1297-301. doi:10.1002/eji.1830161018
12. Slifka MK, Ahmed R. B cell responses and immune memory. Dev Biol Stand (1998) 95:105-15.
13. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med (2007) 357:1903-15. doi:10.1056/NEJMoa066092
14. Cocco M, Stephenson S, Care MA, Newton D, Barnes NA, Davison A, et al. In vitro generation of long-lived human plasma cells. J Immunol (2012) 189(12):5773-85. doi:10.4049/jimmunol.1103720
15. Engel FB, Schebesta M, Duong MT, Lu G, Ren S, Madwed JB, et al. p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev (2005) 19:1175-87.
16. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, et al. Evidence for cardiomyocyte renewal in humans. Science (2009) 324:98-102. doi:10.1126/science.1164680
17. Malato Y, Naqvi S, Schurmann N, Ng R, Wang B, Zape J, et al. Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest (2011) 121:4850-60. doi:10.1172/JCI59261
18. Napoli I, Noon LA, Ribeiro S, Kerai AP, Parrinello S, Rosenberg LH, et al. A central role for the ERK-signaling pathway in controlling Schwann cell plasticity and peripheral nerve regeneration in vivo. Neuron (2012) 73:729-42. doi:10.1016/j.neuron.2011.11.031
19. Senyo SE, Steinhauser ML, Pizzimenti CL, Yang VK, Cai L, Wang M, et al. Mammalian heart renewal by pre-existing cardiomyocytes. Nature (2013) 493:433-6. doi:10.1038/nature11682
20. Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci (2007) 10:1538-43. doi:10.1038/nn2014
21. Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity (2013) 38:792-804. doi:10.1016/j.immuni.2013.04.004
22. Sieweke MH, Allen JE. Beyond stem cells: self-renewal of differentiated macrophages. Science (2013) 342(6161):1242974. doi:10.1126/science.1242974
23. Jelinek DF, Lipsky PE. The role of B cell proliferation in the generation of immunoglobulin-secreting cells in man. J Immunol (1983) 130:2597-604.
24. Brieva JA, Roldan E, de la Sen ML, Rodriguez C. Human in vivo-induced spontaneous IgG-secreting cells from tonsil, blood and bone marrow exhibit different phenotype and functional level of maturation. Immunology (1991) 72:580-3.
25. Roldan E, Brieva JA. Terminal differentiation of human bone marrow cells capable of spontaneous and high-rate immunoglobulin secretion: role of bone marrow stromal cells and interleukin 6. Eur J Immunol (1991) 21:2671-7. doi:10.1002/eji.1830211105
26. Mei HE, Yoshida T, Sime W, Hiepe F, Thiele K, Manz RA, et al. Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood (2009) 113:2461-9. doi:10.1182/blood-2008-04-153544
27. Robillard N, Pellat-Deceunynck C, Bataille R. Phenotypic characterization of the human myeloma cell growth fraction. Blood (2005) 105:4845-8. doi:10.1182/blood-2004-12-4700
28. Mayle A, Luo M, Jeong M, Goodell MA. Flow cytometry analysis of murine hematopoietic stem cells. Cytometry A (2013) 83:27-37. doi:10.1002/cyto.a.22093
29. Morse L, Chen D, Franklin D, Xiong Y, Chen-Kiang S. Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. Immunity (1997) 6:47-56. doi:10.1016/S1074-7613(00)80241-1
30. Tourigny MR, Ursini-Siegel J, Lee H, Toellner KM, Cunningham AF, Franklin DS, et al. CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. Immunity (2002) 17:179-89. doi:10.1016/S1074-7613(02)00364-3
31. Jourdan M, Caraux A, De Vos J, Fiol G, Larroque M, Cognot C, et al. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood (2009) 114:5173-81. doi:10.1182/blood-2009-07-235960
32. Moser K, Tokoyoda K, Radbruch A, Maclennan I, Manz RA. Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol (2006) 18:265-70. doi:10.1016/j.coi.2006.03.004
33. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol (2006) 6:741-50. doi:10.1038/nri1886
34. Tokoyoda K, Egawa T, Sugiyama T, Choi BI, Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity (2004) 20:707-18. doi:10.1016/j.immuni.2004.05.001
35. Geffroy-Luseau A, Jego G, Bataille R, Campion L, Pellat-Deceunynck C. Osteoclasts support the survival of human plasma cells in vitro. Int Immunol (2008) 20:775-82. doi:10.1093/intimm/dxn035
36. Winter O, Moser K, Mohr E, Zotos D, Kaminski H, Szyska M, et al. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood (2010) 116:1867-75. doi:10.1182/blood-2009-12-259457
37. Chu VT, Frohlich A, Steinhauser G, Scheel T, Roch T, Fillatreau S, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol (2011) 12:151-9. doi:10.1038/ni.1981
38. Belnoue E, Tougne C, Rochat AF, Lambert PH, Pinschewer DD, Siegrist CA. Homing and adhesion patterns determine the cellular composition of the bone marrow plasma cell niche. J Immunol (2012) 188:1283-91. doi:10.4049/jimmunol.1103169
39. Winter O, Dame C, Jundt F, Hiepe F. Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy. J Immunol (2012) 189:5105-11. doi:10.4049/jimmunol.1202317
40. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell (2004) 118:149-61. doi:10.1016/j.cell.2004.07.004
41. Qian H, Buza-Vidas N, Hyland CD, Jensen CT, Antonchuk J, Mansson R, et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell (2007) 1:671-84. doi:10.1016/j.stem.2007.10.008
42. Yoshihara H, Arai F, Hosokawa K, Hagiwara T, Takubo K, Nakamura Y, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell (2007) 1:685-97. doi:10.1016/j.stem.2007.10.020
43. Fleming HE, Janzen V, Lo Celso C, Guo J, Leahy KM, Kronenberg HM, et al. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell (2008) 2:274-83. doi:10.1016/j.stem.2008.01.003
44. Yamazaki S, Ema H, Karlsson G, Yamaguchi T, Miyoshi H, Shioda S, et al. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell (2011) 147:1146-58. doi:10.1016/j.cell.2011.09.053
45. Vernino L, McAnally LM, Ramberg J, Lipsky PE. Generation of nondividing high rate Ig-secreting plasma cells in cultures of human B cells stimulated with anti-CD3-activated T cells. J Immunol (1992) 148:404-10.
46. Hodgkin PD, Lee JH, Lyons AB. B cell differentiation and isotype switching is related to division cycle number. J Exp Med (1996) 184:277-81. doi:10.1084/jem.184.1.277
47. Tangye SG, Hodgkin PD. Divide and conquer: the importance of cell division in regulating B-cell responses. Immunology (2004) 112:509-20. doi:10.1111/j.1365-2567.2004.01950.x
48. Duffy KR, Wellard CJ, Markham JF, Zhou JH, Holmberg R, Hawkins ED, et al. Activation-induced B cell fates are selected by intracellular stochastic competition. Science (2012) 335:338-41. doi:10.1126/science.1213230
49. Miller JP, Yeh N, Vidal A, Koff A. Interweaving the cell cycle machinery with cell differentiation. Cell Cycle (2007) 6:2932-8. doi:10.4161/cc.6.23.5042
50. Bretz J, Garcia J, Huang X, Kang L, Zhang Y, Toellner KM, et al. Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors. Blood (2011) 117:2179-88. doi:10.1182/blood-2010-06-288027
51. Lin Y, Wong K, Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science (1997) 276:596-9. doi:10.1126/science.276.5312.596
52. Lin KI, Lin Y, Calame K. Repression of c-myc is necessary but not sufficient for terminal differentiation of B lymphocytes in vitro. Mol Cell Biol (2000) 20:8684-95. doi:10.1128/MCB.20.23.8684-8695.2000
53. Kallies A, Hasbold J, Tarlinton DM, Dietrich W, Corcoran LM, Hodgkin PD, et al. Plasma cell ontogeny defined by quantitative changes in blimp-1 expression. J Exp Med (2004) 200:967-77. doi:10.1084/jem.20040973
54. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity (2002) 17:51-62. doi:10.1016/S1074-7613(02)00335-7
55. Shapiro-Shelef M, Lin KI, McHeyzer-Williams LJ, Liao J, McHeyzer-Williams MG, Calame K. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity (2003) 19:607-20. doi:10.1016/S1074-7613(03)00267-X
56. Doody GM, Care MA, Burgoyne NJ, Bradford JR, Bota M, Bonifer C, et al. An extended set of PRDM1/BLIMP1 target genes links binding motif type to dynamic repression. Nucleic Acids Res (2010) 38:5336-50. doi:10.1093/nar/gkq268
57. Yu J, Angelin-Duclos C, Greenwood J, Liao J, Calame K. Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. Mol Cell Biol (2000) 20:2592-603. doi:10.1128/MCB.20.7.2592-2603.2000
58. Gyory I, Wu J, Fejer G, Seto E, Wright KL. PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat Immunol (2004) 5:299-308. doi:10.1038/ni1046
59. Ancelin K, Lange UC, Hajkova P, Schneider R, Bannister AJ, Kouzarides T, et al. Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse germ cells. Nat Cell Biol (2006) 8:623-30. doi:10.1038/ncb1413
60. Rutishauser RL, Martins GA, Kalachikov S, Chandele A, Parish IA, Meffre E, et al. Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity (2009) 31(2):296-308. doi:10.1016/j.immuni.2009.05.014
61. Crotty S, Johnston RJ, Schoenberger SP. Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat Immunol (2010) 11:114-20. doi:10.1038/ni.1837
62. Ohinata Y, Payer B, O'Carroll D, Ancelin K, Ono Y, Sano M, et al. Blimp1 is a critical determinant of the germ cell lineage in mice. Nature (2005) 436:207-13. doi:10.1038/nature03813
63. Vincent SD, Dunn NR, Sciammas R, Shapiro-Shalef M, Davis MM, Calame K, et al. The zinc finger transcriptional repressor Blimp1/Prdm1 is dispensable for early axis formation but is required for specification of primordial germ cells in the mouse. Development (2005) 132:1315-25. doi:10.1242/dev.01711
64. Horsley V, O'Carroll D, Tooze R, Ohinata Y, Saitou M, Obukhanych T, et al. Blimp1 defines a progenitor population that governs cellular input to the sebaceous gland. Cell (2006) 126:597-609. doi:10.1016/j.cell.2006.06.048
65. Robertson EJ, Charatsi I, Joyner CJ, Koonce CH, Morgan M, Islam A, et al. Blimp1 regulates development of the posterior forelimb, caudal pharyngeal arches, heart and sensory vibrissae in mice. Development (2007) 134:4335-45. doi:10.1242/dev.012047
66. Usui T, Wakatsuki Y, Matsunaga Y, Kaneko S, Koseki H, Kita T, et al. Overexpression of B cell-specific activator protein (BSAP/Pax-5) in a late B cell is sufficient to suppress differentiation to an Ig high producer cell with plasma cell phenotype. J Immunol (1997) 158:3197-204.
67. Lin KI, Angelin-Duclos C, Kuo TC, Calame K. Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol Cell Biol (2002) 22:4771-80. doi:10.1128/MCB.22.13.4771-4780.2002
68. Mora-Lopez F, Reales E, Brieva JA, Campos-Caro A. Human BSAP and BLIMP1 confirm an autoregulatory feedback loop. Blood (2007) 110:3150-7. doi:10.1182/blood-2007-05-092262
69. Schmidlin H, Diehl SA, Nagasawa M, Scheeren FA, Schotte R, Uittenbogaart CH, et al. Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression. Blood (2008) 112:1804-12. doi:10.1182/blood-2008-01-136440
70. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity (2000) 13:199-212. doi:10.1016/S1074-7613(00)00020-0
71. Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, Calame KL. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol (2004) 173:1158-65.
72. Ochiai K, Katoh Y, Ikura T, Hoshikawa Y, Noda T, Karasuyama H, et al. Plasmacytic transcription factor Blimp-1 is repressed by Bach2 in B cells. J Biol Chem (2006) 281:38226-34. doi:10.1074/jbc.M607592200
73. Igarashi K, Ochiai K, Muto A. Architecture and dynamics of the transcription factor network that regulates B-to-plasma cell differentiation. J Biochem (2007) 141:783-9. doi:10.1093/jb/mvm106
74. Ochiai K, Muto A, Tanaka H, Takahashi S, Igarashi K. Regulation of the plasma cell transcription factor Blimp-1 gene by Bach2 and Bcl6. Int Immunol (2008) 20:453-60. doi:10.1093/intimm/dxn005
75. Muto A, Ochiai K, Kimura Y, Itoh-Nakadai A, Calame KL, Ikebe D, et al. Bach2 represses plasma cell gene regulatory network in B cells to promote antibody class switch. EMBO J (2010) 29:4048-61. doi:10.1038/emboj.2010.257
76. Fujita N, Jaye DL, Geigerman C, Akyildiz A, Mooney MR, Boss JM, et al. MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell (2004) 119:75-86. doi:10.1016/j.cell.2004.09.014
77. Hideshima T, Mitsiades C, Ikeda H, Chauhan D, Raje N, Gorgun G, et al. A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood (2010) 115:3772-5. doi:10.1182/blood-2010-02-270082
78. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest (2012) 122:3456-63. doi:10.1172/JCI61188
79. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer (2012) 12:335-48. doi:10.1038/nrc3257
80. Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood (2011) 117:553-62. doi:10.1182/blood-2010-04-279539
81. Sarkies P, Sale JE. Cellular epigenetic stability and cancer. Trends Genet (2012) 28:118-27. doi:10.1016/j.tig.2011.11.005
82. Montes-Moreno S, Montalban C, Piris MA. Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge. Leuk Lymphoma (2012) 53:185-94. doi:10.3109/10428194.2011.608447
83. Miller FR. The induced development and histogenesis of plasma cells. J Exp Med (1931) 54:333-47. doi:10.1084/jem.54.3.333
84. Narita M, Nunez S, Heard E, Lin AW, Hearn SA, Spector DL, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell (2003) 113:703-16. doi:10.1016/S0092-8674(03)00401-X
85. Ye X, Zerlanko B, Zhang R, Somaiah N, Lipinski M, Salomoni P, et al. Definition of pRB-and p53-dependent and-independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci. Mol Cell Biol (2007) 27:2452-65. doi:10.1128/MCB.01592-06
86. Zhang R, Chen W, Adams PD. Molecular dissection of formation of senescence-associated heterochromatin foci. Mol Cell Biol (2007) 27:2343-58. doi:10.1128/MCB.02019-06
87. Chandra T, Kirschner K, Thuret JY, Pope BD, Ryba T, Newman S, et al. Independence of repressive histone marks and chromatin compaction during senescent heterochromatic layer formation. Mol Cell (2012) 47:203-14. doi:10.1016/j.molcel.2012.06.010
88. Zezula J, Casaccia-Bonnefil P, Ezhevsky SA, Osterhout DJ, Levine JM, Dowdy SF, et al. p21cip1 is required for the differentiation of oligodendrocytes independently of cell cycle withdrawal. EMBO Rep (2001) 2:27-34. doi:10.1093/embo-reports/kve008
89. Chandler H, Peters G. Stressing the cell cycle in senescence and aging. Curr Opin Cell Biol (2013) 25(6):765-71. doi:10.1016/j.ceb.2013.07.005
90. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer (2009) 9:785-97. doi:10.1038/nrc2696
91. Aksoy O, Chicas A, Zeng T, Zhao Z, McCurrach M, Wang X, et al. The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence. Genes Dev (2012) 26:1546-57. doi:10.1101/gad.196238.112
92. Xu X, Bieda M, Jin VX, Rabinovich A, Oberley MJ, Green R, et al. A comprehensive ChIP-chip analysis of E2F1, E2F4, and E2F6 in normal and tumor cells reveals interchangeable roles of E2F family members. Genome Res (2007) 17:1550-61. doi:10.1101/gr.6783507
93. Ogawa H, Ishiguro K, Gaubatz S, Livingston DM, Nakatani Y. A complex with chromatin modifiers that occupies E2F-and Myc-responsive genes in G0 cells. Science (2002) 296:1132-6. doi:10.1126/science.1069861
94. Trimarchi JM, Fairchild B, Wen J, Lees JA. The E2F6 transcription factor is a component of the mammalian Bmi1-containing polycomb complex. Proc Natl Acad Sci U S A (2001) 98:1519-24. doi:10.1073/pnas.98.4.1519
95. Attwooll C, Oddi S, Cartwright P, Prosperini E, Agger K, Steensgaard P, et al. A novel repressive E2F6 complex containing the polycomb group protein, EPC1, that interacts with EZH2 in a proliferation-specific manner. J Biol Chem (2005) 280:1199-208. doi:10.1074/jbc.M412509200
96. Trojer P, Cao AR, Gao Z, Li Y, Zhang J, Xu X, et al. L3MBTL2 protein acts in concert with PcG protein-mediated monoubiquitination of H2A to establish a repressive chromatin structure. Mol Cell (2011) 42:438-50. doi:10.1016/j.molcel.2011.04.004
97. Ren S, Rollins BJ. Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell (2004) 117:239-51. doi:10.1016/S0092-8674(04)00300-9
98. Saxena UH, Powell CM, Fecko JK, Cacioppo R, Chou HS, Cooper GM, et al. Phosphorylation by cyclin C/cyclin-dependent kinase 2 following mitogenic stimulation of murine fibroblasts inhibits transcriptional activity of LSF during G1 progression. Mol Cell Biol (2009) 29:2335-45. doi:10.1128/MCB.00687-08
99. Rickert P, Seghezzi W, Shanahan F, Cho H, Lees E. Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. Oncogene (1996) 12:2631-40.
100. Miyata Y, Liu Y, Jankovic V, Sashida G, Lee JM, Shieh JH, et al. Cyclin C regulates human hematopoietic stem/progenitor cell quiescence. Stem Cells (2010) 28:308-17. doi:10.1002/stem.270
101. Soeiro I, Mohamedali A, Romanska HM, Lea NC, Child ES, Glassford J, et al. p27Kip1 and p130 cooperate to regulate hematopoietic cell proliferation in vivo. Mol Cell Biol (2006) 26:6170-84. doi:10.1128/MCB.02182-05
102. Miyamoto K, Araki KY, Naka K, Arai F, Takubo K, Yamazaki S, et al. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell (2007) 1:101-12. doi:10.1016/j.stem.2007.02.001
103. Thompson BJ, Jankovic V, Gao J, Buonamici S, Vest A, Lee JM, et al. Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med (2008) 205:1395-408. doi:10.1084/jem.20080277
104. Reavie L, Della Gatta G, Crusio K, Aranda-Orgilles B, Buckley SM, Thompson B, et al. Regulation of hematopoietic stem cell differentiation by a single ubiquitin ligase-substrate complex. Nat Immunol (2010) 11:207-15. doi:10.1038/ni.1839
105. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer (2008) 8:83-93. doi:10.1038/nrc2290
106. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci (2007) 120:2479-87. doi:10.1242/jcs.001222
107. Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffer PJ, et al. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol (2002) 22:2025-36. doi:10.1128/MCB.22.7.2025-2036.2002
108. Bakker WJ, Harris IS, Mak TW. FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2. Mol Cell (2007) 28:941-53. doi:10.1016/j.molcel.2007.10.035
109. Kranc KR, Schepers H, Rodrigues NP, Bamforth S, Villadsen E, Ferry H, et al. Cited2 is an essential regulator of adult hematopoietic stem cells. Cell Stem Cell (2009) 5:659-65. doi:10.1016/j.stem.2009.11.001
110. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell (1999) 96:857-68. doi:10.1016/S0092-8674(00)80595-4
111. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol (2001) 21:952-65. doi:10.1128/MCB.21.3.952-965.2001
112. Omori SA, Cato MH, Anzelon-Mills A, Puri KD, Shapiro-Shelef M, Calame K, et al. Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity (2006) 25:545-57. doi:10.1016/j.immuni.2006.08.015
113. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 113:5412-7. doi:10.1182/blood-2008-12-194241
114. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood (2009) 113:5418-22. doi:10.1182/blood-2008-12-195008
115. Agarwal A, Ghobrial IM. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res (2013) 19:985-94. doi:10.1158/1078-0432.CCR-12-2922
116. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood (2012) 120:1060-6. doi:10.1182/blood-2012-01-405977
117. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, et al. Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 120:1067-76. doi:10.1182/blood-2012-01-405985
118. Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia (2013). doi:10.1038/leu.2013.199
119. Billadeau D, Ahmann G, Greipp P, Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med (1993) 178:1023-31. doi:10.1084/jem.178.3.1023
120. Pilarski LM, Seeberger K, Coupland RW, Eshpeter A, Keats JJ, Taylor BJ, et al. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol (2002) 30:221-8. doi:10.1016/S0301-472X(01)00788-3
121. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood (2004) 103:2332-6. doi:10.1182/blood-2003-09-3064
122. Huff CA, Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol (2008) 26:2895-900. doi:10.1200/JCO.2007.15.8428
123. Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell (2013) 24:289-304. doi:10.1016/j.ccr.2013.08.009
124. Rasmussen T. The presence of circulating clonal CD19+ cells in multiple myeloma. Leuk Lymphoma (2001) 42:1359-66.
125. Rasmussen T, Lodahl M, Hancke S, Johnsen HE. In multiple myeloma clonotypic CD38-/CD19+/CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes. Leuk Lymphoma (2004) 45:1413-7.
126. Thiago LS, Perez-Andres M, Balanzategui A, Sarasquete ME, Paiva B, Jara-Acevedo M, et al. Circulating clonotypic B-cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica (2013). doi:10.3324/haematol.2013.092817
127. Rasmussen T, Haaber J, Dahl IM, Knudsen LM, Kerndrup GB, Lodahl M, et al. Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma. Haematologica (2010) 95:1730-7. doi:10.3324/haematol.2010.024778
128. Yata K, Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia (2004) 18:1891-7. doi:10.1038/sj.leu.2403513
129. Hosen N, Matsuoka Y, Kishida S, Nakata J, Mizutani Y, Hasegawa K, et al. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia (2012) 26:2135-41. doi:10.1038/leu.2012.80
130. Chaidos A, Barnes CP, Cowan G, May PC, Melo V, Hatjiharissi E, et al. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood (2013) 121:318-28. doi:10.1182/blood-2012-06-436220
131. Hosen N. Multiple myeloma-initiating cells. Int J Hematol (2013) 97:306-12. doi:10.1007/s12185-013-1293-0
132. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 106:296-303. doi:10.1182/blood-2005-01-0034
133. Bienvenu F, Jirawatnotai S, Elias JE, Meyer CA, Mizeracka K, Marson A, et al. Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen. Nature (2010) 463:374-8. doi:10.1038/nature08684
134. Casimiro MC, Crosariol M, Loro E, Ertel A, Yu Z, Dampier W, et al. ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice. J Clin Invest (2012) 122:833-43. doi:10.1172/JCI60256
135. Fearon DT, Manders P, Wagner SD. Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science (2001) 293:248-50. doi:10.1126/science.1062589
136. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med (2011) 17:1290-7. doi:10.1038/nm.2446